Novo Nordisk

News

After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track.

News

Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.

News

Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics.

News

Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.

News

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.

News

Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.